

Xpert MTB/RIF Ultra assay for active pulmonary tuberculosis and rifampicin resistance in children younger than 10 years of age, systematic review update

Alexander W Kay¹, Tara Ness¹, Yemisi Takwoingi², Karen R Steingart³

¹Global Tuberculosis Program, Baylor College of Medicine, Houston, Texas, USA

²Institute of Applied Health Research, University of Birmingham, Birmingham, UK

³Honorary Research Fellow, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK



Baylor
College of
Medicine


Background

- Child TB accounts for 12% of the 10 million global cases and a disproportionate share of TB mortality (over 16%)
- It is estimated that 56% of all child TB cases and 65% in children < 5 years are not diagnosed, in part due to challenging specimen collection
- A Cochrane Review informed the WHO 'Molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children: Policy update 2020'.
- Xpert Ultra diagnostic accuracy for child PTB using sputum and nasopharyngeal specimens
 - Sputum (3 studies, 697 participants): Pooled sensitivity 73% (95% CI 65% to 80%), Pooled specificity 97% (95%CI 96% to 98%)
 - Nasopharyngeal (1 study, 195 participants): Sensitivity 46% (95% CI: 29% to 63%), Specificity 98% (95% CI: 94% to 99%)
- **We performed a systematic review update as additional Xpert Ultra studies have been published on important specimens not included in the original review**

PICO 2b: What is the diagnostic accuracy of Xpert Ultra in gastric aspirate and stool specimens for pulmonary TB in children aged below 10 years, as compared with microbiologic reference standard (MRS) and composite reference standard (CRS)?

- Population: Children 0 to 9 years
 - Age stratification:
 - Less than 1 year
 - 1 to 4 years
 - 5 to 9 years
 - Sub-populations:
 - Children with severe acute malnutrition
 - Children living with HIV
 - Children with severe acute pneumonia

PRISMA Diagram



Identification of studies, data collection and analysis

- We searched multiple databases to 27 January 2021 without language restriction
- Two review authors independently screened titles and abstract and full-text publications
- We systematically contacted all **primary study** authors of identified articles for stratified data and study characteristics
- We identified unpublished data outside of our search results through conversations with child TB experts
- We accepted unpublished data if it was cleaned and considered final by the **primary study authors**
- Meta-analyses were performed using a bivariate random-effects model

Characteristics of Included Studies

- Xpert Ultra Gastric Aspirate or Lavage Specimens
 - 6 studies
 - 50% took place in a high TB burden country and 83% in a high TB/HIV burden country
 - Median prevalence of confirmed TB was 7%
 - One study limited enrollment to HIV+ children and one to children with severe acute malnutrition
- Xpert Ultra Stool Specimens
 - 6 studies
 - 100% took place in a high TB burden country and 83% in a high TB/HIV burden country
 - Median prevalence of confirmed TB was 5%
 - One study limited enrollment to HIV+ children and one to children with severe acute malnutrition

Characteristics of Included Studies

| Study | Countries | High TB burden/high TB/HIV burden | Clinical setting | Type of specimen | Study design | Patient selection | Number of cultures | Composite reference standard |
|------------------|---|-----------------------------------|--------------------------|-----------------------------|--------------------|--------------------------|--------------------|------------------------------|
| FIND 2021 | India, Uganda, South Africa | Yes/Yes | Inpatient and outpatient | Stool | Prospective cohort | Consecutive and referral | Multiple | No |
| Jaganath 2021 | Uganda | No/Yes | Inpatient and outpatient | Gastric aspirate | Prospective cohort | Consecutive | Multiple | Yes |
| Kabir 2020 | Bangladesh | Yes/No | Inpatient | Stool | Cross-sectional | Consecutive | Single | Yes |
| Liu 2020 | China | Yes/Yes | Inpatient and outpatient | Gastric aspirate Stool | Prospective cohort | Consecutive | Multiple | Yes |
| NCT04121026 2021 | Côte d'Ivoire, Mozambique, Uganda, Zambia | Yes/Yes | Inpatient and outpatient | Gastric aspirate Stool | Prospective cohort | Consecutive | Multiple | No |
| NCT04203628 2020 | Uganda and Zambia | Yes/Yes | Inpatient and outpatient | Stool | Prospective cohort | Consecutive | Multiple | No |
| NCT04240990 2021 | Uganda and Zambia | Yes/Yes | Inpatient | Gastric aspirate Stool | Prospective cohort | Consecutive | Multiple | No |
| Parigi 2021 | Italy | No/No | Inpatient | Gastric aspirate | Prospective cohort | Unclear | Multiple | Yes |
| Ssenooba 2020 | Uganda | No/Yes | Outpatient | Gastric aspirate and lavage | Prospective cohort | Consecutive | Multiple | Yes |

QUADAS-2 Assessment of Methodological Quality

Risk of Bias

- Enrolment strategy: prospective, consecutive
- Multiple cultures as compared to a single culture

Applicability

- Enrolment site
- Index test procedure
- Was cultured mycobacteria confirmed as MTB








| | <u>Risk of Bias</u> | | | | <u>Applicability Concerns</u> | | |
|----------------|---------------------|------------|--------------------|-----------------|-------------------------------|------------|--------------------|
| | Patient Selection | Index Test | Reference Standard | Flow and Timing | Patient Selection | Index Test | Reference Standard |
| FIND 2021 | + | + | + | + | + | ? | + |
| Jaganath 2021 | + | + | + | + | + | + | + |
| Kabir 2020 | + | + | ? | + | - | ? | ? |
| Liu 2021 | + | + | + | - | + | ? | ? |
| NCT04121026 | + | + | + | + | + | ? | ? |
| NCT04203628 | + | + | + | + | + | ? | + |
| NCT04240990 | + | + | + | + | ? | ? | ? |
| Parigi 2021 | ? | + | + | + | - | + | ? |
| Ssengooba 2020 | + | + | + | + | + | + | + |

- High
 ? Unclear
 + Low

PICO Sub-questions; Gastric
Aspirate/Lavage Specimens

Should Xpert Ultra in gastric aspirate be used to diagnose pulmonary tuberculosis in children aged below 10 years, against a MRS?

6 studies, 659 participants
 Reference standard: Liquid or solid culture on a sputum specimen collected through gastric aspiration or lavage
 (Median TB prevalence 7%)
Pooled sensitivity: 63.6% (47.7 to 77.0) | Pooled specificity: 94.9% (83.8 to 98.5)

| Study | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) |
|---------------|----|----|----|-----|----------------------|----------------------|---|---|
| Jaganath 2021 | 0 | 3 | 1 | 21 | 0.00 [0.00, 0.97] | 0.88 [0.68, 0.97] |  |  |
| NCT04240990 | 2 | 1 | 3 | 215 | 0.40 [0.05, 0.85] | 1.00 [0.97, 1.00] |  |  |
| Ssenooba 2020 | 11 | 12 | 9 | 203 | 0.55 [0.32, 0.77] | 0.94 [0.90, 0.97] |  |  |
| Liu 2021 | 18 | 9 | 7 | 46 | 0.72 [0.51, 0.88] | 0.84 [0.71, 0.92] |  |  |
| Parigi 2021 | 13 | 5 | 3 | 16 | 0.81 [0.54, 0.96] | 0.76 [0.53, 0.92] |  |  |
| NCT04121026 | 3 | 0 | 0 | 58 | 1.00 [0.29, 1.00] | 1.00 [0.94, 1.00] |  |  |

Should Xpert Ultra in gastric aspirate be used to diagnose pulmonary tuberculosis in children aged below 10 years, against a MRS?

6 studies, 659 participants
 Reference standard: Liquid or solid culture on a sputum specimen collected through gastric aspiration or lavage
 (Median TB prevalence 7%)
Pooled sensitivity: 63.6% (47.7 to 77.0) | Pooled specificity: 94.9% (83.8 to 98.5)

| Test result | Number of results per 1,000 patients tested (95% CI) | | | Number of participants (studies) | Certainty of the Evidence (GRADE) |
|-----------------|--|------------------|------------------|----------------------------------|-----------------------------------|
| | Prevalence 1% | Prevalence 10% | Prevalence 20% | | |
| True positives | 6 (5 to 8) | 64 (48 to 77) | 128 (96 to 154) | 70 (6) | ⊕⊕⊕○ MODERATE ^a |
| False negatives | 4 (2 to 5) | 36 (23 to 52) | 72 (46 to 104) | | |
| True negatives | 941 (832 to 980) | 855 (756 to 891) | 760 (672 to 792) | 589 (6) | ⊕⊕⊕○ MODERATE ^{b,c} |
| False positives | 49 (10 to 158) | 45 (9 to 144) | 40 (8 to 128) | | |

Should Xpert Ultra in gastric aspirate be used to diagnose pulmonary tuberculosis in children aged below 10 years, against a CRS?

3 studies, 142 participants

Reference Standard: A positive culture on a respiratory specimen *OR* a clinical decision to treat for tuberculosis

OR TB as defined by a research definition

(Median TB prevalence 71%)

Pooled sensitivity: 47.5% (38.0 to 57.2) | Pooled specificity: 100% (91.4 to 100)

| Study | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) |
|---------------|----|----|----|----|----------------------|----------------------|---|---|
| Jaganath 2021 | 3 | 0 | 9 | 13 | 0.25 [0.05, 0.57] | 1.00 [0.75, 1.00] |  |  |
| Liu 2021 | 27 | 0 | 30 | 23 | 0.47 [0.34, 0.61] | 1.00 [0.85, 1.00] |  |  |
| Parigi 2021 | 18 | 0 | 14 | 5 | 0.56 [0.38, 0.74] | 1.00 [0.48, 1.00] |  |  |

Should Xpert Ultra in gastric aspirate be used to diagnose pulmonary tuberculosis in children aged below 10 years, against a CRS?

3 studies, 142 participants

Reference standard: A positive culture on a respiratory specimen *OR* a clinical decision to treat for tuberculosis
OR TB as defined by a research definition
 (Median TB prevalence 71%)

Pooled sensitivity: 47.5% (38.0 to 57.2) | **Pooled specificity:** 100% (91.4 to 100)

| Test result | Number of results per 1,000 patients tested (95% CI) | | | Number of participants (studies) | Certainty of the Evidence (GRADE) |
|-----------------|--|------------------|------------------|----------------------------------|-----------------------------------|
| | Prevalence 1% | Prevalence 10% | Prevalence 20% | | |
| True positives | 5 (4 to 6) | 48 (38 to 57) | 96 (76 to 114) | 101 (3) | ⊕⊕○○ LOW ^{a,b} |
| False negatives | 5 (4 to 6) | 52 (43 to 62) | 104 (86 to 124) | | |
| True negatives | 990 (901 to 990) | 900 (819 to 900) | 800 (728 to 800) | 41 (3) | ⊕⊕○○ LOW ^{b,c} |
| False positives | 0 (0 to 89) | 0 (0 to 81) | 0 (0 to 72) | | |

PICO Sub-questions; Stool Specimens

Stool Study Processing Methods and Non-Determinates

| Study | Method | Reference standard | Proportion of non-determinate results* |
|--------------|------------------------------|--|--|
| FIND 2021 | Stool processing kit | Respiratory specimen culture(s) and Xpert Ultra | 10% (42/434) |
| Kabir 2020 | Centrifuge based method | Respiratory specimen culture (solid), Xpert Ultra, and Xpert MTB/RIF | < 1% (1/446) |
| NCT 04240990 | Optimized sucrose floatation | Respiratory specimen culture(s) and Xpert Ultra | 1% (2/237) |
| Liu 2021 | Sedimentation and filtration | Respiratory specimen culture(s) and Xpert Ultra and Xpert MTB/RIF | Not reported |
| NCT 04121026 | Optimized sucrose floatation | Respiratory specimen culture(s) and Xpert Ultra | 4% (5/114) |
| NCT 04203628 | Optimized sucrose floatation | Respiratory specimen culture(s) and Xpert Ultra | 3% (2/76) |

*Proportion is reported as a percentage.


A non-determinate Xpert Ultra test result is one that results in an Error, Invalid, or No Result and may be due to an operator error, instrument, or cartridge issue. Non-determinate results were < 1% for gastric aspirates when reported

Should Xpert Ultra in stool be used to diagnose pulmonary tuberculosis in children aged below 10 years, against a MRS?

6 studies, 1278 participants

Reference Standard: Liquid or solid culture or Xpert on a respiratory specimen
(Median TB prevalence 5%)

Pooled sensitivity: 52.8 (35.0 to 69.9) | Pooled specificity: 98.0 (93.4 to 99.4)



Should Xpert Ultra in stool be used to diagnose pulmonary tuberculosis in children aged below 10 years, against a MRS?

6 studies, 1278 participants
 Reference standard: Liquid or solid culture or Xpert on a respiratory specimen
 (Median Prevalence 5%)
Pooled sensitivity: 52.8% (35.0 to 69.9) | **Pooled specificity:** 98.0% (93.4 to 99.4)


| Test result | Number of results per 1,000 patients tested (95% CI) | | | Number of participants (studies) | Certainty of the Evidence (GRADE) |
|-----------------|--|------------------|------------------|----------------------------------|-----------------------------------|
| | Prevalence 1% | Prevalence 10% | Prevalence 20% | | |
| True positives | 5 (3 to 7) | 53 (35 to 70) | 106 (70 to 140) | 153 (6) | ⊕⊕⊕○ MODERATE ^a |
| False negatives | 5 (3 to 7) | 47 (30 to 65) | 94 (60 to 130) | | |
| True negatives | 970 (921 to 980) | 882 (837 to 891) | 784 (744 to 792) | 1125 (6) | ⊕⊕⊕○ MODERATE ^b |
| False positives | 20 (10 to 69) | 18 (9 to 63) | 16 (8 to 56) | | |

Should Xpert Ultra in stool be used to diagnose pulmonary tuberculosis in children aged below 10 years, against a CRS?

2 studies, 511 participants

Reference Standard: Liquid or solid culture or Xpert on a respiratory specimen *OR* a clinical decision to treat for tuberculosis *OR* TB as defined by a research definition
(TB prevalence 9.0% and 70%)

Pooled sensitivity: 47.1% (39.8 to 54.6) | Pooled specificity: 99.7% (97.9 to 100)

| Study | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) |
|------------|----|----|----|-----|----------------------|----------------------|---|---|
| Kabir 2020 | 51 | 0 | 48 | 303 | 0.52 [0.41, 0.62] | 1.00 [0.99, 1.00] |  |  |
| Liu 2021 | 31 | 1 | 44 | 33 | 0.41 [0.30, 0.53] | 0.97 [0.85, 1.00] |  |  |

Should Xpert Ultra in stool be used to diagnose pulmonary tuberculosis in children aged below 10 years, against a CRS?

2 studies, 511 participants

Reference standard: Liquid or solid culture or Xpert on a respiratory specimen *OR* a clinical decision to treat for tuberculosis *OR* TB as defined by a research definition

(TB prevalence 9.0% and 70%)

Pooled sensitivity: 47.1% (39.8 to 54.6) | **Pooled specificity:** 99.7% (97.9 to 100)

| Test result | Number of results per 1,000 patients tested (95% CI) | | | Number of participants (studies) | Certainty of the Evidence (GRADE) |
|-----------------|--|------------------|------------------|----------------------------------|-----------------------------------|
| | Prevalence 1% | Prevalence 10% | Prevalence 20% | | |
| True positives | 5 (4 to 6) | 47 (40 to 55) | 94 (80 to 110) | 174 (2) | ⊕⊕○○ LOW ^{a,b} |
| False negatives | 5 (4 to 6) | 53 (45 to 60) | 106 (90 to 120) | | |
| True negatives | 990 (970 to 990) | 900 (882 to 900) | 800 (784 to 800) | 337 (2) | ⊕⊕○○ LOW ^{b,c} |
| False positives | 0 (0 to 20) | 0 (0 to 18) | 0 (0 to 16) | | |

Xpert Ultra Trace Results

Trace Results: Gastric Aspirates

- Of the total nine studies, eight (89%) reported the number of Xpert Ultra positive results that were trace results.
- The percentage of Ultra trace results, of the total Xpert Ultra positive results, ranged from 0% to 67% (median 52%) in studies evaluating gastric specimens

| Study | Total (TB cases) | Number of trace results | Number of test positives | Trace % (95% CI)* |
|----------------|------------------|-------------------------|--------------------------|---------------------|
| Jaganath 2021 | 25 (1) | 2 | 3 | 66.7 (20.8 to 93.9) |
| Liu 2021 | 80 (25) | 8 | 27 | 29.6 (15.9 to 48.5) |
| NCT04121026 | 61 (3) | 0 | 3 | 0.00 (0.00 to 56.1) |
| NCT04240990 | 221 (5) | 1 | 3 | 33.3 (6.15 to 79.2) |
| Parigi 2021 | 37 (16) | NA | 18 | NA |
| Ssengooba 2020 | 235 (20) | 13 | 23 | 56.5 (36.8 to 74.4) |

NA = not available

Trace Results: Stool Specimens

- The percentage of Ultra trace results, of the total Xpert Ultra positive results, ranged from 0% to 84% (median 52%) in studies evaluating stool specimens.

| Study | Total (TB cases) | Number of trace results | Number of test positives | Trace % (95% CI)* |
|--------------|------------------|-------------------------|--------------------------|---------------------|
| FIND 2021 | 391 (70) | 12 | 31 | 38.7 (23.7 to 56.2) |
| Kabir 2020 | 402 (23) | 43 | 51 | 84.3 (72.0 to 91.8) |
| Liu 2021 | 109 (48) | 14 | 32 | 43.8 (28.2 to 60.7) |
| NCT04121026 | 69 (3) | 0 | 3 | 0.00 (0.00 to 56.1) |
| NCT 04203628 | 74 (3) | 2 | 3 | 66.7 (20.8 to 93.9) |
| NCT04240990 | 234 (7) | 3 | 5 | 60.0 (23.1 to 88.2) |

Summary estimates with and without trace results

| Test, specimen, age group, reference standard | Studies | Total (TB cases) | Pooled sensitivity (95% CI) | Pooled specificity (95% CI) |
|---|----------------|-------------------------|------------------------------------|------------------------------------|
| Xpert Ultra, gastric aspirate, 0 to 9 years, MRS | 6 | 659 (70) | 63.6 (47.7 to 77.0) | 94.9 (83.8 to 98.5) |
| Xpert Ultra, gastric aspirate, 0 to 9 years, MRS (trace results excluded) | 6 | 635 (63) | 59.4 (41.1 to 75.5) | 97.6 (91.1 to 99.4) |
| Xpert Ultra, stool, 0 to 9 years, MRS | 6 | 1279 (154) | 52.8 (35.0 to 69.9) | 98.0 (93.4 to 99.4) |
| Xpert Ultra, stool, 0 to 9 years, MRS (trace results excluded) | 6 | 1206 (130) | 38.1 (27.2 to 50.4) | 99.7 (98.9 to 99.9) |

Rifampicin resistance and sub-populations

- We did not identify any studies that evaluated the diagnostic accuracy of Xpert Ultra for rifampicin resistance.
- We identified four studies (259 participants, 9 with tuberculosis) in children with severe malnutrition and four studies (99 participants, 8 with tuberculosis) in children living with HIV testing gastric aspirates.
- We identified three studies (428 participants, 19 with tuberculosis) in children with severe malnutrition and two studies (100 participants, 3 with tuberculosis) in children living with HIV testing stool.
- The paucity of data meant we could not perform meta-analyses in children living with HIV and children with severe malnutrition*. No studies were identified evaluating gastric aspirate or stool specimens in children with severe pneumonia.

*meta-analysis performed on stool specimens in children with severe malnutrition

Summary of Main Results

- For gastric aspirate, Xpert Ultra sensitivity was 64% in children 0 to 9 years, against MRS. Sensitivity was similar (67%) in children < 1 year and slightly higher (72%) in children 1 to 4 years. Specificity was 94% to 95% in these analyses.
- For stool, Xpert Ultra sensitivity was 53% in children 0 to 9 years, against MRS. Sensitivity was higher (65%) in children < 1 year and lower (43%) in children 1 to 4 years. Specificity was 96% to 98% in these analyses.
- Sensitivity estimates against a composite reference standard were lower for both specimen types.
- Xpert Ultra trace results were common in both gastric aspirate and stool specimens.
- *Authors' conclusions: Overall, Xpert Ultra sensitivity appeared to be slightly higher in gastric aspirate than stool (indirect comparison). Xpert Ultra specificity in both specimens was > 94%. The small numbers of children < 1 and 1 to 4 years in the analyses, limits our confidence in the precision of the estimates for these age groups.*

Summary Table

| Test, specimen, age group, reference standard | Studies | Total (cases) | Pooled sensitivity (95% CI) | Pooled specificity (95% CI) | Positive predictive value (95% CI) | Negative predictive value (95% CI) |
|--|---------|---------------|-----------------------------|-----------------------------|------------------------------------|------------------------------------|
| Xpert Ultra, gastric aspirate, 0 to 9 years, MRS | 6 | 659 (70) | 63.6 (47.7 to 77.0) | 94.9 (83.8 to 98.5) | 57.9 (31.0 to 80.9) | 95.9 (94.1 to 97.2) |
| Xpert Ultra, gastric aspirate, 0 to 9 years, CRS | 3 | 142 (101) | 47.5 (38.0 to 57.2) | 100 (91.4 to 100)* | 100 (32.9 to 100) | 94.5 (93.0 to 95.5) |
| Xpert Ultra, gastric aspirate, < 1 year, MRS | 5 | 182 (26) | 67.3 (43.5 to 84.6) | 94.0 (84.7 to 97.8) | 55.4 (31.5 to 77.1) | 96.3 (93.1 to 98.0) |
| Xpert Ultra, gastric aspirate, 1 to 4 years, MRS | 4 | 327 (30) | 71.5 (40.0 to 90.4) | 94.0 (73.8 to 98.9) | 57.1 (25.1 to 84.1) | 96.8 (92.5 to 98.6) |
| Xpert Ultra, stool, 0 to 9 years, MRS | 6 | 1279 (154) | 52.8 (35.0 to 69.9) | 98.0 (93.4 to 99.4) | 74.1 (55.2 to 96.6) | 94.9 (92.7 to 96.6) |
| Xpert Ultra, stool, 0 to 9 years, CRS | 2 | 511 (174) | 47.1 (39.8 to 54.6) | 99.7 (97.9 to 100) | 94.6 (71.2 to 99.2) | 94.4 (93.7 to 95.1) |
| Xpert Ultra, stool, < 1 year, MRS | 4 | 295 (31) | 65.2 (33.7 to 87.3) | 96.2 (88.9 to 98.7) | 65.3 (40.2 to 84.0) | 96.2 (91.5 to 98.3) |
| Xpert Ultra, stool, 1 to 4 years, MRS | 3 | 331 (30) | 43.3 (27.1 to 61.2) | 97.1 (74.8 to 99.7) | 62.7 (13.2 to 94.9) | 93.9 (91.8 to 95.5) |
| Xpert Ultra, stool, severe malnutrition, 0 to 9, MRS | 3 | 428 (19) | 63.2 (40.3 to 81.3) | 98.5 (84.1 to 99.9) | 82.3 (27.7 to 98.3) | 96.1 (93.1 to 97.7) |

Questions?

Thank you:

- WHO Child TB team for their support throughout this review
- The Cochrane Review team: Lucia González Fernández, Michael Eisenhut, Anne Detjen and Anna Mandalakas
- Dr Sayera Banu, Programme on Emerging Infections, Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh, and her research team
- The FIND stool diagnostic study for sharing unpublished data
- The TB SPEED study consortium for sharing unpublished data
- All study authors who kindly provided stratified data of their study results




Additional Age Stratified Analyses for Gastric Aspirates and Stool Specimens

Should Xpert Ultra in gastric aspirate be used to diagnose pulmonary tuberculosis in children aged below 1 year, against a MRS?

5 studies, 182 participants

Reference Standard: Liquid or solid culture on a sputum specimen collected through gastric aspiration or lavage (Median TB prevalence 9%)

Pooled sensitivity: 67.3% (43.5 to 84.6) | Pooled specificity: 94.0% (84.7 to 97.8)

| Study | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) |
|----------------|----|----|----|----|----------------------|----------------------|---|---|
| NCT04240990 | 0 | 1 | 1 | 79 | 0.00 [0.00, 0.97] | 0.99 [0.93, 1.00] |  |  |
| Liu 2021 | 10 | 4 | 5 | 24 | 0.67 [0.38, 0.88] | 0.86 [0.67, 0.96] |  |  |
| Ssengooba 2020 | 6 | 3 | 2 | 33 | 0.75 [0.35, 0.97] | 0.92 [0.78, 0.98] |  |  |
| NCT04121026 | 1 | 0 | 0 | 7 | 1.00 [0.03, 1.00] | 1.00 [0.59, 1.00] |  |  |
| Parigi 2021 | 1 | 1 | 0 | 4 | 1.00 [0.03, 1.00] | 0.80 [0.28, 0.99] |  |  |
| Jaganath 2021 | 0 | 0 | 0 | 3 | Not estimable | 1.00 [0.29, 1.00] |  |  |

Should Xpert Ultra in gastric aspirate be used to diagnose pulmonary tuberculosis in children aged below 1 year, against a MRS?

5 studies, 182 participants
 Reference standard: Liquid or solid culture on a sputum specimen collected through gastric aspiration or lavage (Median TB prevalence 9%)
Pooled sensitivity: 67.3% (43.5 to 84.6) | Pooled specificity: 94.0% (84.7 to 97.8)


| Test result | Number of results per 1,000 patients tested (95% CI) | | | Number of participants (studies) | Certainty of the Evidence (GRADE) |
|-----------------|--|-------------------------------------|-------------------------------------|----------------------------------|-----------------------------------|
| | Prevalence 1% Typically seen in | Prevalence 10% Typically seen in | Prevalence 20% Typically seen in | | |
| True positives | 7 (4 to 9) | 67 (44 to 85) | 134 (88 to 170) | 26 (5) | ⊕⊕○○ LOW ^a |
| False negatives | 3 (1 to 6) | 33 (15 to 56) | 66 (30 to 112) | | |
| True negatives | 931 (842 to 970) | 846 (765 to 882) | 752 (680 to 784) | 156 (5) | ⊕⊕⊕○ MODERATE ^b |
| False positives | 59 (20 to 148) | 54 (18 to 135) | 48 (16 to 120) | | |

Should Xpert Ultra in gastric aspirate be used to diagnose pulmonary tuberculosis in children aged 1 to 4 years against a MRS?

4 studies, 327 participants

Reference Standard: Liquid or solid culture on a sputum specimen collected through gastric aspiration or lavage (Median TB prevalence 20%)

Pooled sensitivity: 71.5% (40.0 to 90.4) | Pooled specificity: 94.0% (73.8 to 98.9)



Should Xpert Ultra in gastric aspirate be used to diagnose pulmonary tuberculosis in children aged 1 to 4 years against a MRS?

4 studies, 327 participants


Reference standard: Liquid or solid culture on a sputum specimen collected through gastric aspiration or lavage (Median TB prevalence 20%)

Pooled sensitivity: 71.5% (40.0 to 90.4) | **Pooled specificity:** 94.0% (73.8 to 98.9)

| Test result | Number of results per 1,000 patients tested (95% CI) | | | Number of participants (studies) | Certainty of the Evidence (GRADE) |
|-----------------|--|-------------------------------------|-------------------------------------|----------------------------------|-----------------------------------|
| | Prevalence 1% Typically seen in | Prevalence 10% Typically seen in | Prevalence 20% Typically seen in | | |
| True positives | 7 (4 to 9) | 72 (40 to 90) | 144 (80 to 180) | 30 (4) | ⊕⊕○○ LOW ^a |
| False negatives | 3 (1 to 6) | 28 (10 to 60) | 56 (20 to 120) | | |
| True negatives | 931 (733 to 980) | 846 (666 to 891) | 752 (592 to 792) | 297 (4) | ⊕⊕○○ LOW ^{b,c} |
| False positives | 59 (10 to 257) | 54 (9 to 234) | 48 (8 to 208) | | |

Should Xpert Ultra in stool be used to diagnose pulmonary tuberculosis in children aged below 1 year, against a MRS?

4 studies, 295 participants
 Reference Standard: Liquid or solid culture or Xpert on a respiratory specimen
 (Median TB prevalence 5%)
Pooled sensitivity: 65.2% (33.7 to 87.3) | Pooled specificity: 96.2% (88.9 to 98.7)

| Study | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) |
|-------------|----|----|----|-----|----------------------|----------------------|---|---|
| NCT04240990 | 0 | 1 | 2 | 85 | 0.00 [0.00, 0.84] | 0.99 [0.94, 1.00] |  |  |
| Liu 2021 | 15 | 1 | 7 | 26 | 0.68 [0.45, 0.86] | 0.96 [0.81, 1.00] |  |  |
| Kabir 2020 | 5 | 12 | 1 | 132 | 0.83 [0.36, 1.00] | 0.92 [0.86, 0.96] |  |  |
| NCT04121026 | 1 | 0 | 0 | 7 | 1.00 [0.03, 1.00] | 1.00 [0.59, 1.00] |  |  |

Should Xpert Ultra in stool be used to diagnose pulmonary tuberculosis in children aged below 1 year, against a MRS?

4 studies, 295 participants
 Reference standard: Liquid or solid culture or Xpert on a respiratory specimen
 (Median TB prevalence 5%)
Pooled sensitivity: 65.2% (33.7 to 87.3) | Pooled specificity: 96.2% (88.9 to 98.7)

| Test result | Number of results per 1,000 patients tested (95% CI) | | | Number of participants (studies) | Certainty of the Evidence (GRADE) |
|-----------------|--|----------------------------------|----------------------------------|----------------------------------|-----------------------------------|
| | Prevalence 1% Typically seen in | Prevalence 10% Typically seen in | Prevalence 20% Typically seen in | | |
| True positives | 7 (3 to 9) | 65 (34 to 87) | 130 (68 to 174) | 31 (4) | ⊕○○○ VERY LOW ^{a,b} |
| False negatives | 3 (1 to 7) | 35 (13 to 66) | 70 (26 to 132) | | |
| True negatives | 950 (881 to 980) | 864 (801 to 891) | 768 (712 to 792) | 264 (4) | ⊕⊕⊕○ MODERATE ^c |
| False positives | 40 (10 to 109) | 36 (9 to 99) | 32 (8 to 88) | | |

Should Xpert Ultra in stool be used to diagnose pulmonary tuberculosis in children aged 1 to 4 years, against a MRS?

3 studies, 331 participants
 Reference Standard: Liquid or solid culture or Xpert on a respiratory specimen
 (Median Prevalence 5%)
Pooled sensitivity: 43.3% (27.1 to 61.2) | Pooled specificity: 97.1% (74.8 to 99.7)

| Study | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) |
|-------------|----|----|----|-----|----------------------|----------------------|---|---|
| Kabir 2020 | 2 | 17 | 7 | 120 | 0.22 [0.03, 0.60] | 0.88 [0.81, 0.93] |  |  |
| Liu 2021 | 7 | 2 | 9 | 22 | 0.44 [0.20, 0.70] | 0.92 [0.73, 0.99] |  |  |
| NCT04240990 | 4 | 0 | 1 | 140 | 0.80 [0.28, 0.99] | 1.00 [0.97, 1.00] |  |  |
| NCT04121026 | 0 | 0 | 0 | 41 | Not estimable | 1.00 [0.91, 1.00] | |  |

Should Xpert Ultra in stool be used to diagnose pulmonary tuberculosis in children aged 1 to 4 years, against a MRS?

3 studies, 331 participants
 Reference standard: Liquid or solid culture or Xpert on a respiratory specimen
 (Median TB prevalence 5%)
Pooled sensitivity: 43.3% (27.1 to 61.2) | **Pooled specificity:** 97.1% (74.8 to 99.7)

| Test result | Number of results per 1,000 patients tested (95% CI) | | | Number of participants (studies) | Certainty of the Evidence (GRADE) |
|-----------------|--|-------------------------------------|-------------------------------------|----------------------------------|-----------------------------------|
| | Prevalence 1% Typically seen in | Prevalence 10% Typically seen in | Prevalence 20% Typically seen in | | |
| True positives | 4 (3 to 6) | 43 (27 to 61) | 86 (54 to 122) | 30 (3) | ⊕○○○ VERY LOW ^{a,b} |
| False negatives | 6 (4 to 7) | 57 (39 to 73) | 114 (78 to 146) | | |
| True negatives | 960 (742 to 990) | 873 (675 to 900) | 776 (600 to 800) | 301 (3) | ⊕⊕○○ LOW ^{c,d} |
| False positives | 30 (0 to 248) | 27 (0 to 225) | 24 (0 to 200) | | |